Prodrugs and patents: Enhancing therapy adherence and reducing side effects
As the approval date for Bristol Myers Squibb’s schizophrenia drug KarXT looms, a prodrug approach emerges to potentially address dosing challenges.
Therapy Area
EASD24: Eli Lilly releases Phase III data for once-weekly insulin in diabetes
Integrated Nanotherapeutics gains funds for new T1D treatment
Vir Biotechnology closes Sanofi licence deal for T-cell engagers
EASD24: PolTREG’s T-cell therapy shows long-term remission in type 1 diabetes
Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses
Formosa Pharma ships APP13007 ophthalmic drug to US
Epsilogen secures additional funds in Series B for cancer treatment
